Literature DB >> 34352102

From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?

Paul M Ridker1.   

Abstract

Entities:  

Keywords:  Atherosclerosis; C-reactive protein; Coronary artery disease; Cytokines; Inflammation; Interleukin-6

Mesh：

Substances：

Year:  2021        PMID： 34352102      PMCID： PMC8861265          DOI： 10.1093/cvr/cvab231

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  15 in total

1.  Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.

Authors:  Paul M Ridker; Jean G MacFadyen; Robert J Glynn; Wolfgang Koenig; Peter Libby; Brendan M Everett; Martin Lefkowitz; Tom Thuren; Jan H Cornel
Journal:  J Am Coll Cardiol       Date:  2018-05-29       Impact factor: 24.094

2.  Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study.

Authors:  Tianxi Cai; Yichi Zhang; Yuk-Lam Ho; Nicholas Link; Jiehuan Sun; Jie Huang; Tianrun A Cai; Scott Damrauer; Yuri Ahuja; Jacqueline Honerlaw; Jie Huang; Lauren Costa; Petra Schubert; Chuan Hong; David Gagnon; Yan V Sun; J Michael Gaziano; Peter Wilson; Kelly Cho; Philip Tsao; Christopher J O'Donnell; Katherine P Liao
Journal:  JAMA Cardiol       Date:  2018-09-01       Impact factor: 14.676

3.  Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.

Authors:  Paul M Ridker; Jean G MacFadyen; Brendan M Everett; Peter Libby; Tom Thuren; Robert J Glynn
Journal:  Lancet       Date:  2017-11-13       Impact factor: 79.321

4.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

5.  Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.

Authors:  Brendan M Everett; Jan H Cornel; Mitja Lainscak; Stefan D Anker; Antonio Abbate; Tom Thuren; Peter Libby; Robert J Glynn; Paul M Ridker
Journal:  Circulation       Date:  2019-03-05       Impact factor: 29.690

6.  IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans.

Authors:  Nike Müller; Dominik M Schulte; Kathrin Türk; Sandra Freitag-Wolf; Jochen Hampe; Rainald Zeuner; Johann O Schröder; Ioanna Gouni-Berthold; Heiner K Berthold; Wilhelm Krone; Stefan Rose-John; Stefan Schreiber; Matthias Laudes
Journal:  J Lipid Res       Date:  2015-02-21       Impact factor: 5.922

7.  Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).

Authors:  Paul M Ridker; Peter Libby; Jean G MacFadyen; Tom Thuren; Christie Ballantyne; Francisco Fonseca; Wolfgang Koenig; Hiroaki Shimokawa; Brendan M Everett; Robert J Glynn
Journal:  Eur Heart J       Date:  2018-10-07       Impact factor: 29.983

8.  IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.

Authors:  Paul M Ridker; Matt Devalaraja; Florian M M Baeres; Mads D M Engelmann; G Kees Hovingh; Milana Ivkovic; Larry Lo; Douglas Kling; Pablo Pergola; Dominic Raj; Peter Libby; Michael Davidson
Journal:  Lancet       Date:  2021-05-17       Impact factor: 79.321

Review 9.  Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease.

Authors:  Paul M Ridker; Manas Rane
Journal:  Circ Res       Date:  2021-05-17       Impact factor: 17.367

10.  Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.

Authors:  Nadeem Sarwar; Adam S Butterworth; Daniel F Freitag; John Gregson; Peter Willeit; Donal N Gorman; Pei Gao; Danish Saleheen; Augusto Rendon; Christopher P Nelson; Peter S Braund; Alistair S Hall; Daniel I Chasman; Anne Tybjærg-Hansen; John C Chambers; Emelia J Benjamin; Paul W Franks; Robert Clarke; Arthur A M Wilde; Mieke D Trip; Maristella Steri; Jacqueline C M Witteman; Lu Qi; C Ellen van der Schoot; Ulf de Faire; Jeanette Erdmann; Heather M Stringham; Wolfgang Koenig; Daniel J Rader; David Melzer; David Reich; Bruce M Psaty; Marcus E Kleber; Demosthenes B Panagiotakos; Johann Willeit; Patrik Wennberg; Mark Woodward; Svetlana Adamovic; Eric B Rimm; Tom W Meade; Richard F Gillum; Jonathan A Shaffer; Albert Hofman; Altan Onat; Johan Sundström; Sylvia Wassertheil-Smoller; Dan Mellström; John Gallacher; Mary Cushman; Russell P Tracy; Jussi Kauhanen; Magnus Karlsson; Jukka T Salonen; Lars Wilhelmsen; Philippe Amouyel; Bernard Cantin; Lyle G Best; Yoav Ben-Shlomo; JoAnn E Manson; George Davey-Smith; Paul I W de Bakker; Christopher J O'Donnell; James F Wilson; Anthony G Wilson; Themistocles L Assimes; John-Olov Jansson; Claes Ohlsson; Åsa Tivesten; Östen Ljunggren; Muredach P Reilly; Anders Hamsten; Erik Ingelsson; Francois Cambien; Joseph Hung; G Neil Thomas; Michael Boehnke; Heribert Schunkert; Folkert W Asselbergs; John J P Kastelein; Vilmundur Gudnason; Veikko Salomaa; Tamara B Harris; Jaspal S Kooner; Kristine H Allin; Børge G Nordestgaard; Jemma C Hopewell; Alison H Goodall; Paul M Ridker; Hilma Hólm; Hugh Watkins; Willem H Ouwehand; Nilesh J Samani; Stephen Kaptoge; Emanuele Di Angelantonio; Olivier Harari; John Danesh
Journal:  Lancet       Date:  2012-03-14       Impact factor: 79.321
View more
  2 in total

1.  Interleukin-6 Predicts Carotid Plaque Severity, Vulnerability, and Progression.

Authors:  Joseph Kamtchum-Tatuene; Luca Saba; Mirjam R Heldner; Michiel H F Poorthuis; Gert J de Borst; Tatjana Rundek; Stavros K Kakkos; Seemant Chaturvedi; Raffi Topakian; Joseph F Polak; Glen C Jickling
Journal:  Circ Res       Date:  2022-06-17       Impact factor: 23.213

Review 2.  Fibrotic Signaling in Cardiac Fibroblasts and Vascular Smooth Muscle Cells: The Dual Roles of Fibrosis in HFpEF and CAD.

Authors:  Julian C Bachmann; Simon J Baumgart; Anna K Uryga; Markus H Bosteen; Giulia Borghetti; Michael Nyberg; Kate M Herum
Journal:  Cells       Date:  2022-05-17       Impact factor: 7.666
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.